CD73抑制剂奥来鲁单抗联合奥希替尼治疗经治晚期T790M阴性EGFR突变NSCLC:简要报告
这项1b-2期研究评估抗CD73抗体奥来鲁单抗联合第三代EGFR酪氨酸激酶抑制剂奥希替尼,用于第一/二代EGFR TKI进展后、T790M阴性且未接受过奥希替尼的晚期EGFR突变NSCLC患者。DL1组5例、DL2组21例,未发生剂量限制性毒性、严重治疗相关不良事件或死亡;DL2为推荐2期剂量。在肿瘤和ctDNA均T790M阴性的患者中,客观缓解率DL1组为25.0%、DL2组为11.8%,DL2组中位无进展生存期7.4个月、中位总生存期24.8个月。
要点
- DL1组5例、DL2组21例,未发生剂量限制性毒性、严重治疗相关不良事件或死亡。
- 肿瘤和ctDNA均T790M阴性者客观缓解率DL1组25.0%、DL2组11.8%,均为部分缓解。
- DL2组(排除ctDNA T790M阳性者)中位无进展生存期7.4个月、中位总生存期24.8个月。
核心结论
- 奥来鲁单抗联合奥希替尼在经治晚期EGFR突变NSCLC中显示中等活性且耐受性可接受。
研究设计与样本
- 1b-2期研究(NCT03381274),纳入组织T790M阴性、携带TKI敏感EGFR突变、第一或第二代EGFR TKI进展后且未接受过奥希替尼的晚期NSCLC患者。
- 患者接受奥希替尼80 mg口服每日一次联合奥来鲁单抗1500 mg(DL1)或3000 mg(DL2)静脉每2周一次。
- 主要终点为安全性和按实体瘤疗效评价标准1.1版评估的客观缓解率;截至2021年7月9日,DL1组5例、DL2组21例。
主要发现
- DL1组和DL2组任何级别治疗相关不良事件发生率分别为60.0%和85.7%,3级治疗相关不良事件发生率分别为20.0%和14.3%。
- 未发生剂量限制性毒性、严重治疗相关不良事件或死亡。
- 4例回顾性ctDNA检测为T790M阳性,其中3例达到客观部分缓解。
- 肿瘤和ctDNA均T790M阴性的患者中,客观缓解率DL1组为25.0%、DL2组为11.8%(均为部分缓解);DL2组缓解持续时间为14.8个月和16.6个月。
- DL2组中排除ctDNA T790M阳性者后,中位无进展生存期7.4个月,中位总生存期24.8个月。
关键数值与推荐
- DL2为推荐2期剂量。
- 肿瘤和ctDNA均T790M阴性者客观缓解率:DL1组25.0% vs DL2组11.8%。
- DL2组(排除ctDNA T790M阳性者)中位无进展生存期7.4个月、中位总生存期24.8个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: CD73 is overexpressed in EGFR-mutated NSCLC and may promote immune evasion, suggesting potential for combining CD73 blockers with EGFR tyrosine kinase inhibitors (TKIs). This phase 1b-2 study (NCT03381274) evaluated the anti-CD73 antibody oleclumab plus the third-generation EGFR TKI osimertinib in advanced EGFR-mutated NSCLC. METHODS: Patients had tissue T790M-negative NSCLC with TKI-sensitive EGFR mutations after progression on a first- or second-generation EGFR TKI and were osimertinib naive. They received osimertinib 80 mg orally once daily plus oleclumab 1500 mg (dose level 1 [DL1]) or 3000 mg (DL2) intravenously every 2 weeks. Primary end points included safety and objective response rate by Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: By July 9, 2021, five patients received DL1 and 21 received DL2. Of these patients, 60.0% and 85.7% had any-grade treatment-related adverse events (TRAEs) and 20.0% and 14.3% had grade 3 TRAEs, respectively. No dose-limiting toxicities, serious TRAEs, or deaths occurred. Four patients were T790M positive on retrospective circulating tumor DNA (ctDNA) testing; three had objective partial responses. In patients who were T790M negative in tumor and ctDNA, objective response rate was 25.0% at DL1 and 11.8% at DL2 (all partial responses); response durations at DL2 were 14.8 and 16.6 months. In patients receiving DL2, excluding those who were T790M positive by ctDNA, median progression-free survival was 7.4 months, and median overall survival was 24.8 months. DL2 was the recommended phase 2 dose. CONCLUSIONS: Oleclumab plus osimertinib was found to have moderate activity with acceptable tolerability in previously treated patients with advanced EGFR-mutated NSCLC.
引用
- Kim DW, Kim SW, Camidge DR, et al. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. J Thorac Oncol. 2023. PMID: 36641093. doi:10.1016/j.jtho.2022.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。